At the news
? BEARISHIMPACT 4/10 COURT-RULING filed Feb 8, 2026 at 19:00 ET
The District Court for the Northern District of California granted Defendants' motion to dismiss all six causes of action in PTC Therapeutics' trade secret misappropriation lawsuit against AcureX Biosciences and former employees. The court found PTC failed to plausibly allege misappropriation and did not describe its trade secrets with sufficient particularity, but granted leave to amend by February 20, 2026. This procedural setback weakens PTC's IP enforcement efforts but does not represent a final loss or immediate financial impact.
- Court granted motion to dismiss all six claims (DTSA, CUTSA, breach of contract, implied covenant, UCL, declaratory judgment) for failure to state a claim.
- PTC's allegations of trade secret misappropriation were deemed conclusory and reliant on an impermissible 'inevitable disclosure' theory.
- PTC identified two trade secrets with sufficient particularity but failed to plausibly allege misappropriation of those secrets.
- Leave to amend granted; amended complaint must be filed by February 20, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access